BUZZ-Tectonic Therapeutic soars on prelim pulmonary hypertension drug data

** Shares of drug developer Tectonic Therapeutic TECX.O rise ~104% to $52.50, set for record single-day pct gain

** TECX says its experimental drug, TX45, showed improved blood flow and reduced pressure in lungs and heart in an early-stage trial

** TECX is testing TX45 to treat patients with group 2 pulmonary hypertension, a condition where high lung blood pressure is caused by left-sided heart disease, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and feet

** TX45 was well-tolerated and had no serious side effects in patients - TECX

** The condition currently has no approved treatments

** TECX more than doubled in 2024